Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19

• Main Authors: Yasmin Silva-Santos (Author), Roberta Liberato Pagni (Author), Thais Helena Martins Gamon (Author), Marcela Santiago Pacheco de Azevedo (Author), Mônica Bielavsky (Author), Maria Laura Goussain Darido (Author), Danielle Bruna Leal de Oliveira (Author), Edmarcia Elisa de Souza (Author), Carsten Wrenger (Author), Edson Luiz Durigon (Author), Maria Cecília Rui Luvizotto (Author), Hans Christian Ackerman (Author), Claudio Romero Farias Marinho (Author), Sabrina Epiphanio (Author), Leonardo José Moura Carvalho (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

COVID-19 causes more severe and frequently fatal disease in patients with pre-existing comorbidities such as hypertension and heart disease. SARS-CoV-2 virus enters host cells through the angiotensin-converting enzyme 2 (ACE2), which is fundamental in maintaining arterial pressure through the renin-...